Universita degli Studi di Firenze - Azienda Ospedaliero-Universitaria Careggi (AOUC) LAB TMO
Welcome,         Profile    Billing    Logout  
 2 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Olavarria, Eduardo L
ALLELE, NCT03394365 / 2017-002949-30: Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

Checkmark Data from ALLELE trial for post-transplant lymphoproliferative disease
Dec 2021 - Dec 2021: Data from ALLELE trial for post-transplant lymphoproliferative disease
Recruiting
3
66
Europe, Canada, US, RoW
tabelecleucel, tab-cel®, ATA129, EBV-CTL
Atara Biotherapeutics
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
08/25
06/27
MO-TRANS, NCT05429632 / 2021-002864-36: Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Active, not recruiting
3
249
Europe, Japan, US, RoW
mocravimod
Priothera SAS, Priothera S.A.S.
Adult Acute Myeloid Leukemia
11/25
11/25
ALL-RIC, NCT03821610 / 2017-004800-23: A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission.

Active, not recruiting
2
242
Europe
Fludarabine, Melphalan, Alemtuzumab, Cyclophosphamide, Mesna, Total Body Irradiation (8Gy)
University of Birmingham
Acute Lymphoblastic Leukemia
11/24
11/27
Ingram, Wendy
AMADEUS, NCT04173533 / 2018-001012-30: Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT

Active, not recruiting
3
326
Europe
Oral azacitidine, CC-486, Matched placebo, Oral azacitidine matched placebo
University of Birmingham
Acute Myeloid Leukemia, Myelodysplasia
04/25
04/25
OASIS, NCT05101187: Olorofim Aspergillus Infection Study

Recruiting
3
225
Europe, Canada, Japan, US, RoW
Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)
F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi
Invasive Aspergillosis
09/25
11/26
MO-TRANS, NCT05429632 / 2021-002864-36: Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Active, not recruiting
3
249
Europe, Japan, US, RoW
mocravimod
Priothera SAS, Priothera S.A.S.
Adult Acute Myeloid Leukemia
11/25
11/25
ACHIEVE, NCT05358808: - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)

Recruiting
2
53
Europe
TCB008, CD3+ T cells expressing the γ-chain variable region 9 δ-chain variable region 2 (Vγ9Vδ2) T cell receptor (TCR)
TC Biopharm
Acute Myeloid Leukemia, Myelodysplastic Syndromes
12/25
12/25
PHOEBUS, NCT05762211: Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications ( Trial)

Recruiting
2
387
Europe
Pooled allogeneic fecal microbiotherapy, MaaT033, Placebo
MaaT Pharma
Transplant Complication
10/26
02/27
Sharplin, Kirsty
MO-TRANS, NCT05429632 / 2021-002864-36: Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Active, not recruiting
3
249
Europe, Japan, US, RoW
mocravimod
Priothera SAS, Priothera S.A.S.
Adult Acute Myeloid Leukemia
11/25
11/25

Download Options